Investor profile
Canaan Partners
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Canaan is an early-stage venture capital firm that 'invests in visionaries with transformative ideas' across a deliberate 60/40 technology-to-healthcare split. On the technology side, the firm targets enterprise SaaS, fintech, consumer, frontier tech (robotics, AI/ML, autonomous vehicles, supply chain), and cybersecurity. On the healthcare side, Canaan focuses on biopharma company creation and early investments in oncology, immunology, neurology, cardiology, and respiratory — including de novo company formation alongside experienced scientific teams. Canaan XIII ($650M fund closed April 2023, plus $200M in follow-on reserves) continues the firm's 35-year history of partnering with founders at seed and Series A, with reserves to support companies through IPO or M&A. The firm runs a transparent, debate-driven partnership process and prides itself on being 'the very first to partner with the best entrepreneurs' for the long haul, bringing 130 years of combined operating experience and a diverse team (40% women GPs, 47% immigrants or first-generation Americans).
Notable quotes
“Canaan has always aimed to be the very first to partner with the best entrepreneurs and companies because we have a shared long-term view to build a company together, in the right way and for the long haul.”
“Even if Canaan hadn't funded us, just going through the process with them – the discussions we had and the questions they asked – already made us a better company. And that's amazing.”
“Canaan was a founding investor in Synthekine in 2019, and since the beginning, Julie's thought partnership and strategic advice have been invaluable to our growth into a multiproduct clinical stage company with world class partnerships.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| OpenArt | Series A | $30m | 2025-12 |
| Field AI | Series D | $405m | 2025-08 |
| SageOx | Seed | $15m | 2025 |
| Instacart | IPO | — | 2023-09 |
| Hermeus | Series C | — | 2023 |
| Snyk | Series F | — | 2022 |
| The RealReal | IPO | — | 2019-06 |
| LendingClub | IPO | — | 2014-12 |
| Aeva | Series B | — | 2020 |
| Arvinas | IPO | — | 2018-09 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Khosla Ventures | 8 |
| Andreessen Horowitz | 7 |
| General Catalyst | 6 |
| Bessemer Venture Partners | 6 |
| Accel | 5 |
| First Round Capital | 4 |
Fit check
Is Canaan Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit